['leukemia, lymphocytic, chronic, b-cell', 'lymphoma, large b-cell, diffuse', 'lymphoma, follicular', 'lymphoma, mantle-cell']
['duvortuxizumab', 'ibrutinib']

        Inclusion Criteria:

          -  The participant has a B-cell malignancy (diffuse large B-cell lymphoma [DLBCL],
             follicular lymphoma [FL], mantle cell lymphoma [MCL], or chronic lymphocytic leukemia
             [CLL]) with tumor progression following at least one (MCL and CLL) or two (DLBCL and
             FL) prior standard therapies

          -  The participant has a radiographically measurable tumor that requires treatment
             according to the treating physician

          -  The participant is able to carry out daily life activities with significant difficulty

          -  The participant has adequate organ and blood cell counts

          -  Sexually active participants must use medically acceptable methods of contraception
             during the course of the study

        Exclusion Criteria:

          -  The participant has a brain tumor or significant side effects, including severe
             neurological side effects, from a previous anti-cancer treatment

          -  Current severe, uncontrolled systemic disease including an ongoing, active infection
             or history of clinically significant heart problems

          -  History of autoimmune disease, allogeneic hematopoietic stem cell transplant, or organ
             transplant

          -  The participant has received any of the following: ibrutinib or other Bruton's
             tyrosine kinase (BTK) inhibitor at any time; an agent targeting CD19-positive cells or
             CD3-expressing T cells at any time; or warfarin, a vitamin K antagonist, or a blood
             transfusion (red blood cells and/or platelets) within 1 week of starting the study

          -  The participant is pregnant, breastfeeding, or planning to become pregnant or father a
             child
      